Abstract
Most of the currently used diagnostics for cancerous diseases have yet to meet the standards of screening, as they are insufficiently accurate and/or invasive and risky. In this review, we describe the rationale, the progress made to date, and the potential of analysing the exhaled volatile organic compounds as a pathway for enabling early diagnosis of cancer and, therefore, for achieving better clinical prognosis and survival rates. The review highlights the major advancements made in this field, from fundamentals, up to translational phases and clinical trials, with a special emphasis on sensing platforms based on nanomaterials. The prospects for breath analysis in early cancerous disease are presented and discussed.
Abstract
Breath volatolomics is a highly promising frontier in non-/minimally invasive personalised and evidence-based cancer medicine that could be implemented for a wide variety of cancers in a noninvasive, affordable and easy-to-use manner http://bit.ly/2XeMsDb
Footnotes
Provenance: Submitted article, peer reviewed.
Conflict of interest: R. Einoch Amor has nothing to disclose.
Conflict of interest: M.K. Nakhleh has nothing to disclose.
Conflict of interest: O. Barash has nothing to disclose.
Conflict of interest: H. Haick has nothing to disclose.
- Received January 10, 2019.
- Accepted May 19, 2019.
- Copyright ©ERS 2019.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.